RedChip Companies’ Post

September is World Alzheimer's Month. Current research sets the clinical trial failure rate of Alzheimer's drugs at 99.6%. At Axol, we want to move the dial on this number using the power of human iPSCs. Stay tuned for a month of posts to raise awareness of this increasingly common, debilitating condition and the work we're doing to accelerate and de-risk Alzheimer's drug discovery using human iPSCs. https://hubs.la/Q020FCNf0 #iPSCs #AlzheimersDisease #StemCells #DrugDiscovery #ClinicalTrialInADish

TrueBinding was recently featured in Inside Health Policy, shedding light on the exploration of innovative alternatives to the current anti-amyloid drug class, with the aim of not only curbing cognitive decline but also minimizing potential side effects. Alzheimer's is a complex condition not solely driven by amyloid plaque formation. Clinical studies suggest that our investigational treatment, TB006, has the potential to address neuroinflammation, another key contributor. By blocking Galectin-3, TB006 suppresses inflammation and potentially dissolves plaques. Encouraging early clinical data has demonstrated benefits even in a short timeframe (one month, in moderate-to-severe clinical trial participants). TrueBinding's journey continues with a Phase 2B clinical trial planned for the end of 2023, aimed at garnering more substantial insights. Click the link to read the full article: bit.ly/3qKJASr

🌍 Today, on International Psoriasis Day, let's shine a light on a condition that often remains hidden. Psoriasis affects approximately 2-3% of the world's population and has a profound impact on their quality of life. 🤝 On this day of solidarity and awareness, ETAP-Lab stands in support of psoriasis patients. We recognize the challenges they face every day. 🧪 At ETAP-Lab, we're already actively engaged in the battle against psoriasis. Our efforts in developing and providing translational preclinical research services are driven by our deep-rooted desire to enhance the quality of life for patients. 🔬 Our team is proud to contribute to the preclinical development of new therapeutics that hold the promise of improving health outcomes. Please share this post to spread awareness far and wide. 🔄 #InternationalPsoriasisDay #ETAPLab #PsoriasisAwareness #ResearchForACure #ShareForChange

Could human iPSCs help us to tackle the 99.6% failure rate for Alzheimer's Disease drug discovery? In this excerpt from our webinar "Tackling the Alzheimer's 99.6% problem", our Product Manager Dr Jan Turner explains the challenges for Alzheimer's Disease (AD) drug discovery. Our vision is to develop an AD "clinical trial in a dish" model comprising a large, diverse collection of patient samples to increase statistical power and enable patient stratification. To hear more about this, access the full webinar recording here: https://hubs.la/Q02xxm9F0 #iPSCs #AlzheimersDisease #ClinicalTrialInADish #PatientStratification #StemCells

𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐭𝐡𝐞 𝐠𝐥𝐨𝐛𝐚𝐥 𝐥𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞 𝐨𝐟 𝐏𝐚𝐫𝐤𝐢𝐧𝐬𝐨𝐧'𝐬 𝐦𝐚𝐧𝐚𝐠𝐞𝐦𝐞𝐧𝐭, 𝐢𝐝𝐞𝐧𝐭𝐢𝐟𝐲𝐢𝐧𝐠 𝐞𝐦𝐞𝐫𝐠𝐢𝐧𝐠 𝐭𝐫𝐞𝐧𝐝𝐬 𝐚𝐧𝐝 𝐢𝐧𝐯𝐞𝐬𝐭𝐦𝐞𝐧𝐭 𝐨𝐩𝐩𝐨𝐫𝐭𝐮𝐧𝐢𝐭𝐢𝐞𝐬 𝐢𝐧 𝐭𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐟𝐨𝐫 𝐞𝐧𝐡𝐚𝐧𝐜𝐞𝐝 𝐩𝐚𝐭𝐢𝐞𝐧𝐭 𝐜𝐚𝐫𝐞 𝐚𝐧𝐝 𝐧𝐞𝐮𝐫𝐨𝐥𝐨𝐠𝐢𝐜𝐚𝐥 𝐡𝐞𝐚𝐥𝐭𝐡 𝐚𝐝𝐯𝐚𝐧𝐜𝐞𝐦𝐞𝐧𝐭𝐬. Our comprehensive market report explores Parkinson's Disease dynamics within neurological disorders, highlighting holistic management strategies for symptomatic relief and tailored interventions. Navigate timely identification and precision treatment approaches to improve patient outcomes. Stay updated on innovative therapies and overcome challenges in Parkinson's management to drive advancements in neurological health. Report Link: https://lnkd.in/gqSQZ7mA Ask for customization: https://lnkd.in/d6q8Q-5a #ParkinsonDisease #MarketReport #Clinicaltrial #PatentAnalysis #MarketForecast #MarketInsight #pharmaceuticalsReport #Wissenresearch #Pharmaceuticals

🌟 Exciting Research Discovery! 🌟 New study reveals lansoprazole, a widely-used proton pump inhibitor, may protect against liver injury caused by isoniazid, a common antitubercular drug. 🧬 Using innovative approaches including zebrafish models and patient health records, researchers at Mie University identified LPZ's potential in mitigating drug-induced liver injury. 🐟🔬 Stay tuned for more updates on this promising avenue for drug repositioning! #LiverHealth #DrugDiscovery #ScienceNews

Could human iPSCs help us to tackle the 99.6% failure rate for Alzheimer's Disease drug discovery? In this excerpt from our webinar "Tackling the Alzheimer's 99.6% problem", our Product Manager Dr Jan Turner explains the challenges for Alzheimer's Disease (AD) drug discovery. Our vision is to develop an AD "clinical trial in a dish" model comprising a large, diverse collection of patient samples to increase statistical power and enable patient stratification. To hear more about this, access the full webinar recording here: https://hubs.la/Q02xxm6Q0 #iPSCs #AlzheimersDisease #ClinicalTrialInADish #PatientStratification #StemCells

September is World Alzheimer's Month. Current research sets the clinical trial failure rate of Alzheimer's drugs at 99.6%. At Axol, we want to move the dial on this number using the power of human iPSCs. Stay tuned for a month of posts to raise awareness of this increasingly common, debilitating condition and the work we're doing to accelerate and de-risk Alzheimer's drug discovery using human iPSCs. https://hubs.la/Q020FBY60 #iPSCs #AlzheimersDisease #StemCells #DrugDiscovery #ClinicalTrialInADish

Alzheimer’s Disease Scientists/Researcher’s Could human iPSCs help us to tackle the 99.6% failure rate for Alzheimer's Disease drug discovery? In this excerpt from our webinar "Tackling the Alzheimer's 99.6% problem", our Product Manager Dr Jan Turner explains the challenges for Alzheimer's Disease (AD) drug discovery. Our vision is to develop an AD "clinical trial in a dish" model comprising a large, diverse collection of patient samples to increase statistical power and enable patient stratification. To hear more about this, access the full webinar recording here: https://hubs.la/Q02xxm6Q0 #CNS #humancells #research #drugdiscovery #drugdevelopment #neuroscience #biopharma #biotech #pharma

Explore the global landscape of Parkinson's management, identifying emerging trends and investment opportunities in therapeutics for enhanced patient care and neurological health advancements. Our comprehensive market report explores Parkinson's Disease dynamics within neurological disorders highlighting holistic management strategies for symptomatic relief and tailored interventions. Navigate timely identification and precision treatment approaches to improve patient outcomes Stay updated on innovative therapies and overcome challenges in Parkinson's management to drive advancements in neurological health Report Link: https://lnkd.in/gqSQZ7mA Ask for customization: https://lnkd.in/d6q8Q-5a #ParkinsonDisease #MarketReport #Clinicaltrial #PatentAnalysis #MarketForecast #Marketlnsight #pharmaceuticalsReport #Wissenresearch #Pharmaceuticals